+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Global Clinical Trials Review, H1, 2020

  • ID: 5118387
  • Clinical Trials
  • May 2020
  • Region: Global
  • 183 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Altor Bioscience LLC
  • Anchiano Therapeutics Ltd
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • CG Oncology Inc
  • Liminal BioSciences Inc
  • MORE
Summary

The publisher's clinical trial report, “Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Global Clinical Trials Review, H1, 2020" provides an overview of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The publisher's Clinical Trial Reports are generated using the publisher's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to Buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Altor Bioscience LLC
  • Anchiano Therapeutics Ltd
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • CG Oncology Inc
  • Liminal BioSciences Inc
  • MORE
Report Guidance

Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
  • Feb 25, 2020: Theralase advances its pivotal phase II non-muscle invasive bladder cancer study with a new clinical study site in Nova Scotia
  • Clinical Trial Profile Snapshots
Appendix
  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About the Publisher
  • Contact
  • Disclaimer
  • Source
List of Tables
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Region, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, North America, Top Countries, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Central and South America, Top Countries, 2020*
  • Proportion of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) to Oncology Clinical Trials, G7 Countries (%), 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) to Oncology Clinical Trials, E7 Countries (%), 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Phase, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
List of Figures
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Region (%), 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, North America, Top Countries (%), 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2020*
  • Proportion of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) to Oncology Clinical Trials, G7 Countries (%), 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) to Oncology Clinical Trials, E7 Countries (%), 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Phase (%), 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
  • Methodology
Note: Product cover images may vary from those shown
3 of 3
  • UroGen Pharma Ltd
  • Merck & Co Inc
  • Spectrum Pharmaceuticals Inc
  • Anchiano Therapeutics Ltd
  • Asieris Pharmaceuticals Co Ltd
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Liminal BioSciences Inc
  • CG Oncology Inc
  • Altor Bioscience LLC
Note: Product cover images may vary from those shown
Adroll
adroll